Blandine Padey

Lyon, 69007, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Host-targeted repurposed diltiazem enhances the antiviral activity of direct acting antivirals against Influenza A virus and SARS-CoV-2.

Host-targeted repurposed diltiazem enhances the antiviral activity of direct acting antivirals against Influenza A virus and SARS-CoV-2.

Journal: Antiviral research

Published: November 30, 2024

Interactions Between Severe Acute Respiratory Syndrome Coronavirus 2 Replication and Major Respiratory Viruses in Human Nasal Epithelium.

Interactions Between Severe Acute Respiratory Syndrome Coronavirus 2 Replication and Major Respiratory Viruses in Human Nasal Epithelium.

Journal: The Journal of infectious diseases

Published: June 02, 2022

Autoantibodies against type I IFNs in patients with critical influenza pneumonia.

Autoantibodies against type I IFNs in patients with critical influenza pneumonia.

Journal: The Journal of experimental medicine

Published: March 22, 2022

Molnupiravir combined with different repurposed drugs further inhibits SARS-CoV-2 infection in human nasal epithelium in vitro.

Molnupiravir combined with different repurposed drugs further inhibits SARS-CoV-2 infection in human nasal epithelium in vitro.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: January 19, 2022

Avian Cell Line DuckCelt®-T17 Is an Efficient Production System for Live-Attenuated Human Metapneumovirus Vaccine Candidate Metavac®.

Avian Cell Line DuckCelt®-T17 Is an Efficient Production System for Live-Attenuated Human Metapneumovirus Vaccine Candidate Metavac®.

Journal: Vaccines

Published: September 13, 2021

Correction: Early nasal type I IFN immunity against SARS-CoV-2 is compromised in patients with autoantibodies against type I IFNs.

Correction: Early nasal type I IFN immunity against SARS-CoV-2 is compromised in patients with autoantibodies against type I IFNs.

Journal: The Journal of experimental medicine

Published: August 20, 2021

Early nasal type I IFN immunity against SARS-CoV-2 is compromised in patients with autoantibodies against type I IFNs.

Early nasal type I IFN immunity against SARS-CoV-2 is compromised in patients with autoantibodies against type I IFNs.

Journal: The Journal of experimental medicine

Published: June 03, 2021

Transcriptional Profiling of Immune and Inflammatory Responses in the Context of SARS-CoV-2 Fungal Superinfection in a Human Airway Epithelial Model.

Transcriptional Profiling of Immune and Inflammatory Responses in the Context of SARS-CoV-2 Fungal Superinfection in a Human Airway Epithelial Model.

Journal: Microorganisms

Published: November 03, 2020

In Vitro Combinations of Baloxavir Acid and Other Inhibitors against Seasonal Influenza A Viruses.

In Vitro Combinations of Baloxavir Acid and Other Inhibitors against Seasonal Influenza A Viruses.

Journal: Viruses

Published: September 21, 2020

Human Respiratory Syncytial Virus-Induced Immune Signature of Infection Revealed by Transcriptome Analysis of Clinical Pediatric Nasopharyngeal Swab Samples.

Human Respiratory Syncytial Virus-Induced Immune Signature of Infection Revealed by Transcriptome Analysis of Clinical Pediatric Nasopharyngeal Swab Samples.

Journal: The Journal of infectious diseases

Published: May 23, 2020

In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2.

In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2.

Journal: Antiviral research

Published: May 06, 2020

Characterization and Treatment of SARS-CoV-2 in Nasal and Bronchial Human Airway Epithelia.

Characterization and Treatment of SARS-CoV-2 in Nasal and Bronchial Human Airway Epithelia.

Journal: Cell reports. Medicine

Published: April 22, 2020

Showing 1-12 of 18

Last Updated: 09/26/2026